Drug Trial Radar · NCT05873751
A Study to Learn About How Trumenba Vaccine Shots Work Against Gonorrhea Infection in Teenagers and Young Adults in the United States.
Last checked: Nov 19, 2026Latest source record: Apr 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,307,378
Actual
Start
Apr 24, 2023
Primary completion
Mar 31, 2024
Study completion Mar 31, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- May 24, 2023
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 15 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Brief Summary: The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection. This study looks at data records from a database in the United States. This study includes patient's data from the database who: * Are 15-30 years old. * Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine. This data has already been collected in the past and is being studied between April and June of 2023.
Conditions
- Gonorrhea
- Chlamydia
- Meningococcal Vaccines
Interventions
Trumenba VaccineBiological
Trumenba vaccine given as standard of care
MenACWY VaccineBiological
MenACWY Vaccine given as standard of care
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Gonococcal Infection After at Least 1 Dose of Trumenba to Determine Vaccine Effectiveness (VE)Time frame: During follow-up of maximum of 83.5 months (from 14 days after the index date up to 31 December 2022; available retrospective data evaluated for approximately 11 months of this study)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pfizer
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.